Close Menu

NEW YORK – Less than two weeks ago, members of the Jackson Laboratory's Maine Cancer Genomics Initiative (MCGI) were seeing strong enrollment by cancer patients seeking somatic tumor profiling to inform their treatment or potential clinical trial options.

But MCGI Medical Director and Jax medical oncologist Jens Rueter expects that could soon change, as cancer centers and clinical trial sites across the US and beyond respond to the COVID-19 pandemic.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.